BeOne Medicines
Tracked across 8 events · 65 articles · First seen Apr 13, 2026 · Last active Aug 11, 2026
Live sentiment trends, attention charts, and prominence tracking available on the
Ergen Dashboard
Business
Impact: BeOne Medicines received the 'Outstanding Global Oncology Company of the Year' award, recognizing its advancements in R&D and manufacturing of cancer therapies, which positively impacts its reputation and market standing.
May 11, 2026 · 6 articles
Tech
Impact: BeOne Medicines announced positive topline results from its Phase 3 MANGROVE study for Zanubrutinib, which is expected to significantly boost its market position and future revenue in oncology.
Jun 30, 2026 · 6 articles
Business
BeOne Medicines and Revolution Medicines announced a multi-part collaboration on August 10, 2026. The deal includes a clinical collaboration to evaluate drug combinations combining select BeOne oncology assets with Revolution Medicines' four clinical RAS(ON) inhibitors…
Impact: BeOne gains exclusive rights to develop and commercialize Revolution Medicines' RAS(ON) inhibitors in select Asian markets, strengthening its oncology portfolio and regional presence. It will also fund a Phase 3 study, leveraging its development capabilities.
Aug 10, 2026 · 7 articles
Business
Zymeworks Inc., a biotechnology company, announced that its management will participate in several upcoming investor conferences in September 2026. These include the Wells Fargo Healthcare Conference on September 8 in Boston, Citi's Biopharma Back to…
Impact: BeOne Medicines is a partner of Zymeworks with exclusive rights to develop and commercialize zanidatamab in certain territories. The conference participation does not directly affect BeOne Medicines.
Aug 11, 2026 · 6 articles
Tech
Impact: BeOne Medicines provided Tislelizumab under a clinical drug supply agreement for AnBogen Therapeutics's Phase 1/2 clinical trial.
Apr 13, 2026 · 6 articles
Business
Impact: Dr. Michelle Mellion previously held a Chief Medical Officer role at BeOne Medicines, leading clinical development efforts.
May 12, 2026 · 6 articles
Business
Impact: BeOne Medicines is a partner with exclusive rights to develop and commercialize zanidatamab in certain territories; mentioned in the company description but not directly involved in this event.
Jul 16, 2026 · 6 articles
90
Revolution Medicines granted exclusive rights BeOne MedicinesBeOne and Revolution...
80
BeOne Medicines signed collaboration Revolution MedicinesBeOne and Revolution...
ERGEN INTELLIGENCE
Track BeOne Medicines live
Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.
Open Dashboard